The PTEN tumor suppressor is frequently affected in cancer cells, and inherited PTEN mutation causes cancer-susceptibility conditions such as Cowden syndrome. PTEN acts as a plasma-membrane lipid-phosphatase antagonizing the phosphoinositide 3-kinase/AKT cell survival pathway. However, PTEN is also found in cell nuclei, but mechanism, function, and relevance of nuclear localization remain unclear. We show that nuclear PTEN is essential for tumor suppression and that PTEN nuclear import is mediated by its monoubiquitination. A lysine mutant of PTEN, K289E associated with Cowden syndrome, retains catalytic activity but fails to accumulate in nuclei of patient tissue due to an import defect. We identify this and another lysine residue as major monoubiquitination sites essential for PTEN import. While nuclear PTEN is stable, polyubiquitination leads to its degradation in the cytoplasm. Thus, we identify cancer-associated mutations of PTEN that target its posttranslational modification and demonstrate how a discrete molecular mechanism dictates tumor progression by differentiating between degradation and protection of PTEN.

No abstract

BackgroundMitoQ is a mitochondria-targeted derivative of the antioxidant ubiquinone, with antioxidant and anti-apoptotic functions. Reactive oxygen species are involved in many inflammatory diseases including inflammatory bowel disease. In this study, we assessed the therapeutic effects of MitoQ in a mouse model of experimental colitis and investigated the possible mechanisms underlying its effects on intestinal inflammation.MethodsReactive oxygen species levels and mitochondrial function were measured in blood mononuclear cells of patients with inflammatory bowel disease. The effects of MitoQ were evaluated in a dextran sulfate sodium-induced colitis mouse model. Clinical and pathological markers of disease severity and oxidative injury, and levels of inflammatory cytokines in mouse colonic tissue were measured. The effect of MitoQ on inflammatory cytokines released in the human macrophage-like cell line THP-1 was also analyzed.ResultsCellular and mitochondrial reactive oxygen species levels in mononuclear cells were significantly higher in patients with inflammatory bowel disease (P <0.003, cellular reactive oxygen species; P <0.001, mitochondrial reactive oxygen species). MitoQ significantly ameliorated colitis in the dextran sulfate sodium-induced mouse model in vivo, reduced the increased oxidative stress response (malondialdehyde and 3-nitrotyrosine formation), and suppressed mitochondrial and histopathological injury by decreasing levels of inflammatory cytokines IL-1 beta and IL-18 (P <0.001 and P <0.01 respectively). By decreasing mitochondrial reactive oxygen species, MitoQ also suppressed activation of the NLRP3 inflammasome that was responsible for maturation of IL-1 beta and IL-18. In vitro studies demonstrated that MitoQ decreases IL-1 beta and IL-18 production in human THP-1 cells.ConclusionTaken together, our results suggest that MitoQ may have potential as a novel therapeutic agent for the treatment of acute phases of inflammatory bowel disease.

Mutational alterations of the PTEN gene located on chromosome 10q23.3 have been frequently observed in a variety of human malignancies, including glioblastoma, melanoma, prostate cancer and endometrial cancer. 1-7 PTEN mutations and allelic deletions at 10q23 appear to be late events in glioblastoma, melanoma and prostate cancer, while in thyroid and endometrial cancers, PTEN alterations are found at an early stage, such as endometrial hyperplasia and benign thyroid tumors. 4 -9 Frequent germline or somatic mutations of PTEN have also been found in patients with Cowden disease and Bannayan-Zonana syndrome, which are autosomal dominant disorders characterized by the formation of multiple benign tumors and increased risk of malignant breast and thyroid tumors. 10,11 The PTEN gene encodes a protein product which shares high homology in its N-terminal region with the cytoskeletal protein tensin and the secretary vesicle protein auxilin. 1,2 The PTEN protein also contains a structural motif for a dual-specificity protein phosphatase. 12 PTEN acts as a phospholipid phosphatase, dephosphorylating PIP 3 with specificity for the phosphate group at the D3 position of the inositol ring. 13 PIP 3 is a lipid second messenger produced by PI3-kinase and activates a variety of signaling effectors such as AKT kinase. The lipid phosphatase activity of PTEN is essential for its ability to inhibit tumorigenesis and growth inhibition. 14,15 In human tumor cells lacking wild-type PTEN or in PTEN-deficient mice, PIP 3 levels are increased, leading to enhanced phosphorylation and activation of the survivalpromoting factor AKT kinase, indicating that PTEN exerts its tumor-suppressor function by negatively regulating the antiapoptotic PI3-kinase/AKT signaling pathway. 16 In addition, in immortalized PTEN-deficient mouse embryonic fibroblasts, PTEN restored apoptosis induced by stimuli such as UV irradiation. 17 The role of PTEN as a tumor-suppressor has also been attributed to its ability to modulate cell-cycle progression and cell motility. Expression of wild-type PTEN in PTEN-null glioblastoma or renal cell carcinoma cells causes cell-cycle arrest in the G 1 phase, inhibits colony formation and suppresses tumorigenicity in nude mice. 18 Exogenous expression of PTEN in fibroblasts and a glioma cell line with mutant PTEN alleles also suppresses cell migration, integrin-mediated cell spreading and focal adhesion. 19

Caveolin-1 (CAV1) acts as a growth suppressor in various human malignancies, but its expression is elevated in many advanced cancers, suggesting the oncogenic switch of its role during tumor progression. To understand the molecular basis for the growth-promoting function of CAV1, we characterized its expression status, differential roles for tumor growth, and effect on glucose metabolism in colorectal cancers. Abnormal elevation of CAV1 was detected in a substantial fraction of primary tumors and cell lines and tightly correlated with promoter CpG sites hypomethylation. Depletion of elevated CAV1 led to AMPK activation followed by a p53-dependent G 1 cell-cycle arrest and autophagy, suggesting that elevated CAV1 may contribute to ATP generation. Furthermore, CAV1 depletion downregulated glucose uptake, lactate accumulation, and intracellular ATP level, supporting that aerobic glycolysis is enhanced by CAV1. Consistently, CAV1 was shown to stimulate GLUT3 transcription via an HMGA1-binding site within the GLUT3 promoter. HMGA1 was found to interact with and activate the GLUT3 promoter and CAV1 increased the HMGA1 activity by enhancing its nuclear localization. Ectopic expression of HMGA1 increased glucose uptake, whereas its knockdown caused AMPK activation. In addition, GLUT3 expression was strongly induced by cotransfection of CAV1 and HMGA1, and its overexpression was observed predominantly in tumors harboring high levels of CAV1 and HMGA1. Together, these data show that elevated CAV1 upregulates glucose uptake and ATP production through HMGA1-mediated GLUT3 transcription, suggesting that CAV1 may render tumor cells growth advantages by enhancing aerobic glycolysis. Cancer Res; 72(16); 4097-109. Ó2012 AACR.